A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.

doi:10.1186/s12967-020-02680-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.

Journal of translational medicine - 6 Jan 2021

Simeone Ester, Scognamiglio Giosuè, Capone Mariaelena, Giannarelli Diana, Grimaldi Antonio M, Mallardo Domenico, Madonna Gabriele, Curvietto Marcello, Esposito Assunta, Sandomenico Fabio, Sabbatino Francesco, Bayless Nicholas L, Warren Sarah, Ong SuFey, Botti Gerardo, Flaherty Keith T, Ferrone Soldano, Ascierto Paolo A

Abstract excerpt

BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma may provide therapeutic benefits; MEK inhibition may prevent the reactivation of the MAPK pathway induced by BRAF inhibitor resistance. PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azetidines

Share to GPI-Linked Proteins

Share to Interferons

Share to Melanoma

Share to Piperidines

Share to Skin Neoplasms

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 33407577
DOI: 10.1186/s12967-020-02680-7
PMCID: PMC7789377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.PMID 33407577Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

[BRAF-MEK inhibitor therapy in melanoma].Semantic proximity Read ↗

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Semantic proximity Read ↗

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Semantic proximity Read ↗

BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.Semantic proximity Read ↗

Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.